Introduction {#S1}
============

Drug addiction involves dysregulation in brain reward circuitry leading to compulsive drug use ([@R14]; [@R29]; [@R31]). In addition to drug reward, the mesolimbic dopamine system plays an integral role in relapse to drug-seeking behavior, since stimuli that elicit drug seeking also activate dopamine neurons in the ventral tegmental area (VTA) leading to dopamine release in forebrain regions such as the nucleus accumbens (NAc) ([@R48]; [@R51]; [@R60]; [@R61]; [@R66]; [@R68]). Opioid receptors also play a role in relapse to cocaine seeking in animal models, since systemic treatment with naltrexone inhibits cocaine seeking elicited by exposure to cocaine-associated cues ([@R8]). Similarly, cocaine-primed cocaine seeking is blocked by systemic administration of the partial mu opioid receptor (MOR) agonist buprenorphine, the delta opioid receptor (DOR) antagonist naltrindole, or the nonspecific opioid antagonist naltrexone ([@R11]; [@R20]).

Stewart and colleagues found that opioid receptors in the VTA play a role in reinstatement of cocaine and heroin seeking, since intra-VTA morphine treatments trigger drug seeking in an extinction/reinstatement paradigm ([@R67]), an animal model of relapse. This effect is thought to involve local disinhibition of dopamine neurons in the VTA leading to dopamine release in the NAc ([@R18]; [@R27]; [@R34]). In contrast, previous studies suggest that opioid receptors localized in the NAc do not play a role in drug seeking, since intra-NAc morphine treatments fail to reinstate cocaine- or heroin-seeking ([@R69]; [@R74]), and blockade of NAc MOR with the selective MOR antagonist CTAP failed to significantly alter cocaine-primed reinstatement of cocaine seeking ([@R74]). However, endogenous opioid peptides such as β-endorphin are released in the NAc by cocaine and stressful situations ([@R53]; [@R54]; [@R81]), events that trigger reinstatement of cocaine seeking, and intra-NAc morphine infusions induce a conditioned place preference ([@R78]).

Opioid receptors are highly expressed by NAc neurons ([@R35]; [@R36]), and local opioid infusions in the NAc modulate behavior in a biphasic manner. Thus, microgram doses of DAMGO (MOR agonist) or morphine infused in the NAc initially suppress locomotion but subsequently induce hyper-locomotion ([@R13]; [@R40]). Lower doses of DAMGO decrease the latency for hyper-locomotion to occur ([@R40]). Since doses of agonists used in these locomotor studies are similar to those used in prior reinstatement studies, it is possible that the behavioral suppressive effects masked the potential of NAc opioid receptor stimulation to trigger reinstatement of drug-seeking behavior. Moreover, NAc infusions of opioid agonists induce feeding behavior but also with a prolonged latency to initiate feeding ([@R5]; [@R30]). Similarly, intra-NAc infusions of DAMGO increase the motivation for food on a progressive ratio reinforcement schedule, and where response breakpoints are obtained after some delay ([@R82]). Therefore, it is possible that these delayed motivational effects reflect the initial suppressive effects of high dose MOR agonist infusions.

In this study, we investigated the role of NAc opioid receptors in reinstatement of cocaine-seeking behavior using MOR- and DOR-selective ligands and endogenous opioid peptides. We found that NAc infusions of MOR and DOR agonists effectively reinstate cocaine seeking through selective actions at their respective receptors. Stimulation of NAc opioid receptors by the endogenous peptides β-endorphin and enkephalins also induced cocaine-seeking behavior. The results clearly establish that either MOR or DOR stimulation in the NAc is sufficient to elicit cocaine-seeking behavior, and that MOR receptors play an important role in cocaine-primed relapse. These findings also suggest that persistent neuroadaptations in NAc opioid receptors following chronic cocaine use could contribute to drug-seeking behavior in prolonged abstinence.

Materials and Methods {#S2}
=====================

Animals and housing conditions {#S3}
------------------------------

Male Sprague-Dawley rats weighing 225--275g (Charles River Laboratories, Kingston, NY) were individually housed in wire cages with food and water available ad libitum, except during lever press training. Experiments were conducted during the light cycle of a 12:12-h light:dark cycle (lights on at 0700 hours) in accordance with guidelines established by the National Institute of Health and the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center.

Sucrose Lever Press Training and Surgery {#S4}
----------------------------------------

Lever press training, self-administration, and reinstatement testing were performed in operant test chambers (Med-Associates, East Fairfield, VT). Chambers were equipped with two response levers and an infusion pump as described previously ([@R17]). Animals were food-restricted to prevent weight gain and trained to lever-press for sucrose pellets on a fixed ratio 1 (FR1) reinforcement schedule until an acquisition criteria of 100 sucrose pellets consumed for 3 consecutive test days was reached. Following lever-press training, animals were fed *ad libitum* for at least 1 day prior to surgery. Animals were anesthetized and implanted with a chronic indwelling catheter into the jugular vein that exited subcutaneously on the back. An intra-cranial, 26-guage bilateral guide cannula was aimed at the NAc (±1.5 mm lateral; 1.7 mm anterior to bregma; −5.7 ventral to dura with the level skull) or caudate putamen (±1.5 mm lateral; 1.7 mm anterior to bregma; −3.2 mm ventral to dura) ([@R43]). Dummy and infusion cannulae (33 gauge) were cut to extend 1 mm beyond the guide cannulae tip, and dummy cannulae remained in place until the day of intracranial drug infusion. Animals were allowed 5--7 days to recover prior to starting the experiment.

Cocaine self-administration and within-session reinstatement testing {#S5}
--------------------------------------------------------------------

Animals were tested in a within-session extinction/reinstatement paradigm as described previously ([@R4]). Briefly, animals self-administered cocaine (0.5 mg/kg in 0.1 ml over 5 s, time-out 15 s) in daily 4-h sessions for 5--6 days/week until a criteria of 3 consecutive days of \<10% variance in mean cocaine intake was reached (\~3 weeks). During the 5 s injection a cue light above the lever was illuminated, while the house light was turned off for the entire injection and time-out period. Subsequently, animals were trained in the within-session extinction paradigm that consisted of 1-h cocaine availability followed by 3-h extinction conditions where only response-contingent injection cues were available. Animals extinguished responding to criteria of ≤ 5 responses at either the drug-paired or inactive lever for the final h of the session for at least 3 consecutive sessions, while maintaining a minimum of 15 self-administered cocaine injections with ± 10% variability in the first h of the session. Mean cocaine self-administration on the test day was 25 ± 0.74 (NAc) and 26 ± 0.95 (CPu) injections/h. Test days were conducted with an intra-NAc infusion of MOR and DOR agonists alone (0.5 μl/side over 2 min) or in combination as sequential antagonist/agonist infusions (1.0 μl/side total volume) immediately prior to the final h of the test session. For cocaine priming experiments, animals received NAc or CPu antagonist infusions followed immediately by iv priming with saline (0.4 ml) or cocaine (2.0 mg/kg in 0.4 ml). Following each test day, animals returned to within-session extinction training until stable self-administration and extinction criteria were reached for at least 2 consecutive sessions prior to the next test. Animals received a maximum of 8 intracranial test infusions.

Locomotor testing {#S6}
-----------------

Some animals trained in the within-session reinstatement paradigm were given 1 week off from cocaine self-administration and tested for locomotor responses to agonist infusions in the NAc or CPu using peak doses for reinstatement that were selective for the drug-paired lever. The locomotor testing apparatus consisted of a circular-shaped plexiglass arena with 12 cm wide metal floors (Med-Associates) with four pairs of photocells located at 90-degree intervals around the 1.95 m perimeter to record locomotor activity. Animals were habituated for 2 h in the dark followed by an intra-NAc or intra-CPu drug infusion and returned to the locomotor chambers for 2 h of subsequent testing. Testing of each drug was randomized and done on consecutive days. Animals received 5 injections in locomotor tests.

Histological Confirmation of injection sites {#S7}
--------------------------------------------

Animals were anesthetized with chloral hydrate, and cresyl violet (0.3 μl) was infused into the NAc or CPu through the guide cannula. Animals were immediately decapitated and brains removed. 0.8 mm thick slices were collected throughout the forebrain and analyzed under a dissecting microscope for the location of the infusion sites according to the coordinates of Paxinos and Watson ([@R43]).

Drugs {#S8}
-----

Drugs used were DAMGO (D-Ala^2^,N-Me-Phe^4^,glycinol^5^)-enkephalin), DPDPE ((D-Pen^2^,D-Pen^5^)-Enkephalin), CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH~2~), β-endorphin, met-enkephalin, and thiorphan (Bachem Bioscience Inc., King of Prussia, PA), and naloxone and naltrindole (Sigma-Aldrich, Atlanta, GA). Ligands were dissolved in 0.9% sterile saline except thiorphan which was dissolved in 1:4 DMSO:saline. Cocaine hydrochloride was obtained from the National Institute on Drug Abuse (Research Triangle Park) and dissolved in 0.9% sterile saline.

Statistical Analysis {#S9}
--------------------

Since not all animals completed an experiment, data were analyzed using a 2 factor mixed regression analysis (SAS 9.1.3) of treatment × lever, followed by main effects analysis of each lever separately. Post-Hoc tests utilized 1- or 2-tailed Dunnett's tests where appropriate for comparison with controls and Tukey's honestly significant difference (HSD) test for pair-wise comparison where appropriate. Locomotor data were analyzed by 1-way repeated measures ANOVA on treatment for each h tested. Post-Hoc tests utilized Dunnett's 1-tailed test for comparison with controls.

Results {#S10}
=======

MOR and DOR involvement in reinstatement {#S11}
----------------------------------------

We first determined whether NAc infusions of the MOR-selective agonist DAMGO and the DOR-selective agonist DPDPE could reinstate non-reinforced drug-paired lever responding following extinction of cocaine seeking. Intra-NAc infusions of DAMGO produced an inverted-U shaped dose-response curve ([Figure 1a](#F1){ref-type="fig"}) for non-reinforced responding on the drug-paired but not inactive lever (dose × lever: *F*~6,161~ = 2.37, *p* = 0.032) with a main effect of both dose (*F*~6,161~ = 3.52, *p* = 0.003) and lever (*F*~1,161~ = 46.01, *p* \< 0.001). DAMGO induced moderate peak rates of responding at very low doses (1--3 ng/side) when compared to vehicle infusions without increasing inactive lever responding, whereas higher doses (10 ng/side) led to reduced responding (drug-paired lever: *F*~6,66~ = 3.33, *p* = 0.006; inactive lever: *F*~6,66~ = 1.13, *p* = NS). Similarly, intra-NAc infusions of DPDPE produced an inverted U-shaped dose-response curve ([Figure 1b](#F1){ref-type="fig"}), but induced greater responding and at higher doses of 300--3000 ng/side (dose: *F*~6,113~ = 12.09, *p* \< 0.001; lever: *F*~1,113~ = 28.16, *p* \< 0.001). Unlike DAMGO, DPDPE induced substantial and significant lever pressing of both drug-paired and inactive levers compared to vehicle (drug-paired lever: *F*~6,40~ = 11.37, *p* \< 0.001; inactive lever: *F*~6,40~ = 3.34, *p* = 0.009). Inactive lever responding significantly increased only at the peak dose for drug-paired lever responding (1000 ng/side).

Antagonist inhibition of agonist-mediated reinstatement {#S12}
-------------------------------------------------------

To determine whether DAMGO-stimulated reinstatement of cocaine seeking was mediated by MOR stimulation in the NAc, we tested the ability of the MOR-selective antagonist CTAP to block DAMGO-primed reinstatement using the lowest effective dose from the previous experiment (1 ng/side). Intra-NAc pretreatment of CTAP dose-dependently blocked DAMGO-primed reinstatement ([Figure 2a](#F2){ref-type="fig"}; dose × lever: *F*~6,172~ = 7.82, *p* \< 0.001), with a main effect of dose (*F*~6,172~ = 7.78, *p* \< 0.001) and lever (*F*~1,172~ = 123.36, *p* \< 0.001). Non-reinforced responding at the drug-paired lever was blocked with maximally effective doses as low as 0.1 ng/side of CTAP (drug-paired lever: *F*~6,67~ = 8.59, *p* \< 0.001; inactive lever: *F*~6,67~ = 1.19, *p* = NS). Similarly, we tested the DOR-selective antagonist naltrindole against the lowest effective dose for DPDPE-induced reinstatement that did not increase inactive lever responding (300 ng). [Figure 2b](#F2){ref-type="fig"} shows that intra-NAc treatment of naltrindole reduced DPDPE-primed reinstatement in a dose dependent manner achieving control levels at 1000 ng/side (dose × lever: *F*~4,139~ = 2.85, *p* = 0.026; dose: *F*~4,139~ = 11.35, *p* \< 0.001; lever *F*~1,139~ = 55.54, *p* \< 0.001). Drug-paired lever responding was significantly attenuated starting at 300 ng/side with maximal suppression at 1000 ng/side (*F*~4,58~ = 11.63, *p* \< 0.001). Naltrindole produced some mild suppression of responding on the inactive lever (inactive lever: *F*~4,58~ = 2.48, *p* = 0.05).

Drug specificity and antagonist inhibition of cocaine mediated reinstatement {#S13}
----------------------------------------------------------------------------

To determine whether DAMGO and DPDPE-induced cocaine seeking was specific to MOR or DOR blockade, MOR and DOR agonists and antagonists were tested in a cross-blockade experimental design. Animals were given intra-NAc infusions of DAMGO (1 ng/side or DPDPE (300 ng/side) following pretreatment with maximally effective doses of CTAP (30 ng/side), naltrindole (1000 ng/side), or vehicle. [Figure 3a](#F3){ref-type="fig"} shows that DAMGO-induced reinstatement of drug-paired lever responding was selectively blocked by CTAP but not naltrindole when compared to vehicle (treatment × lever: *F*~2,82~ = 5.09, *p* = 0.008; treatment: *F*~2,82~ = 4.84, *p* = 0.01; lever: *F*~1,82~ = 68.65, *p* \< 0.001). CTAP significantly attenuated drug-paired lever responding (*F*~2,29~ = 5.61, *p* = 0.009) with no effect on inactive lever responding (*F*~2,29~ = 0.40, *p* = NS). Conversely, [Figure 3b](#F3){ref-type="fig"} shows that DPDPE-induced reinstatement was selectively blocked by naltrindole but not CTAP (treatment: *F*~2,40~ = 8.83, *p* \< 0.001; lever: *F*~1,40~ = 39.01, *p* \< 0.001), with attenuation mainly on the drug-paired lever (*F*~2,13~ = 5.65, *p* = 0.017) and a trend for reduction in lower responding on the inactive lever (*F*~2,13~ = 2.87, *p* = 0.092). Together, these results indicate that selective stimulation of either MOR or DOR in the NAc is sufficient to independently trigger cocaine-seeking behavior.

Given that cocaine injections are known to increase endogenous opioid release in the NAc, we tested whether MOR or DOR in the NAc play a role in cocaine-primed reinstatement of cocaine-seeking behavior. Animals were given NAc pretreatments with vehicle, CTAP, or naltrindole immediately prior to an iv cocaine injection (2 mg/kg) in the reinstatement paradigm. Since the peak dose of CTAP (30 ng against 1 ng DAMGO) had no effect on cocaine-primed reinstatement (data not shown), we tested a higher dose of CTAP (3 μg/side) more commonly used in intracranial studies ([@R63]; [@R74]), along with the 1 μg/side dose of naltrindole. CTAP's affinity for MOR (2.36 ± 0.46 nM) is 15.7 times lower than that of naltrindole for DOR (0.15 ± 0.01 nM) ([@R6]; [@R10]; [@R44]; [@R49]), indicating that relatively higher amounts of CTAP than naltrindole may be required to inhibit endogenous opioid activity at MOR than DOR. Furthermore, the doses of CTAP and naltrindole used were roughly molar equivalents (5.4 μM and 4.8 μM, respectively). Intra-NAc pretreatment with CTAP significantly reduced cocaine-primed reinstatement compared to vehicle pretreatment ([Figure 3c](#F3){ref-type="fig"}), whereas pretreatment with naltrindole did not (treatment × lever: *F*~2,82~ = 4.17, *p* = 0.019; treatment: *F*~2,82~ = 5.12, *p* = 0.008; lever: *F*~1,82~ = 62.51, *p* = 0.001). CTAP significantly attenuated drug-paired lever responding in response to an iv cocaine prime without affecting inactive lever responding (drug-paired lever: *F*~2,17~ = 7.08, *p* = 0.006; inactive lever: *F*~2,17~ = 0.38, *p* = NS). These findings indicate that endogenous opioid release in the NAc contributes to cocaine-primed reinstatement of cocaine seeking through activation of MOR but not DOR.

Endogenous opioid peptides reinstate cocaine seeking in the NAc {#S14}
---------------------------------------------------------------

The next set of experiments determined the ability of endogenous opioids to reinstate cocaine seeking using intra-NAc infusions of β-endorphin and met-enkephalin. Intra-NAc infusions of β-endorphin dose-dependently reinstated responding on the cocaine-paired lever with effective doses ranging from 100--1000 ng/side ([Figure 4a](#F4){ref-type="fig"}; dose × lever: *F*~4,103~ = 4.07, *p* = 0.004; dose: *F*~4,103~ = 12.11, *p* \< 0.001; lever: *F*~1,103~ = 51.27, *p* \< 0.001). β-endorphin infusions significantly increased drug-paired lever responding (*F*~4,42~ = 8.82, *p* \< 0.001) with a minor increase in inactive lever responding at the highest dose (inactive lever: *F*~4,42~ = 7.32, *p* \< 0.001). In contrast, intra-NAc infusions of met-enkephalin failed to reinstate cocaine seeking up to doses as high as 10 μg/side ([Figure 4b](#F4){ref-type="fig"}; *F*~5,102~ = 0.44, *p* = NS). Since previous studies used enkephalin derivatives, suggesting that enkephalins are degraded too rapidly to produce effects in behavioral tests ([@R28]; [@R47]), we used the enkephalinase inhibitor thiorphan to determine if the accumulation of endogenously released enkephalins would reinstate cocaine seeking. Intra-NAc thiorphan infusions effectively reinstated responding to levels similar to β-endorphin ([Figure 4c](#F4){ref-type="fig"}; dose: *F*~4,92~ = 6.77, *p* \< 0.001; lever: *F*~1,92~ = 63.27, *p* \< 0.001). Thiorphan induced prominent responding on the drug-paired lever (*F*~4,36~ = 4.55, *p* = 0.004) with minor increases in responding on the inactive lever at the peak dose of 3.0 μg that approached significance (*F*~4,36~ = 2.48, *p* = 0.061). These findings indicate that either MOR-preferring (β-endorphin) or DOR-preferring (enkephalins) endogenous opioid peptides in the NAc are capable of eliciting cocaine-seeking behavior.

Receptor specificity of endogenous opioid-induced reinstatement of cocaine seeking {#S15}
----------------------------------------------------------------------------------

While β-endorphin and enkephalins preferentially interact with MOR and DOR respectively, they also interact with other opioid receptors. We tested the ability of 3 μg CTAP, 1 μg naltrindole, and the less specific opioid antagonist naloxone to block β-endorphin- and thiorphan-induced reinstatement. Animals were given NAc infusions of maximally effective doses of β-endorphin (1 μg/side) or thiorphan (3 μg/side) immediately following vehicle, CTAP (3 μg/side), naltrindole (1 μg/side), or naloxone (10 μg/side) pretreatments. [Figure 5a](#F5){ref-type="fig"} shows that β-endorphin-induced reinstatement of cocaine seeking was selectively attenuated by CTAP or naloxone, but not naltrindole (treatment × lever: *F*~3,74~ = 4.83, *p* = 0.004; treatment: *F*~3,74~ = 10.45, *p* \< 0.001; lever: *F*~1,74~ = 66.94, *p* \< 0.001), specifically reducing responding on the drug-paired lever (*F*~3,27~ = 12.63, *p* \< 0.001) and not inactive lever (*F*~3,27~ = 0.94, *p* = NS). Conversely, [Figure 5b](#F5){ref-type="fig"} shows that reinstatement elicited by the enkephalinase inhibitor thiorphan was blocked selectively by naltrindole or naloxone, but not significantly by CTAP (treatment: *F*~3,69~ = 5.55, *p* = 0.002; lever: *F*~1,69~ = 15.19, *p* \< 0.001). Naltrindole and naloxone reduced thiorphan-induced responding on the drug-paired and not inactive lever (drug-paired lever: *F*~3,26~ = 4.45, *p* = 0.012; inactive lever: *F*~3,26~ = 2.23, *p* = NS). Thus, the endogenous opioid peptide β-endorphin reinstates cocaine seeking through selective activation of NAc MOR, while elevations in endogenous enkephalin levels trigger cocaine seeking primarily through DOR activation, consistent with their preference for these receptors.

Regional specificity for MOR- but not DOR-induced reinstatement of cocaine-seeking behavior {#S16}
-------------------------------------------------------------------------------------------

To determine whether MOR and DOR stimulation of cocaine seeking was specific to the NAc, or due to potential spread up the cannulae shaft, we infused effective doses of all agonists 2.5 mm dorsal to the NAc site in the caudate putamen (CPu), a region shown to have similar expression patterns of opioid receptors as the NAc. While none of the MOR-acting agonists or the enkephalinase inhibitor induced reinstatement in the CPu ([Figure 6a](#F6){ref-type="fig"}), CPu infusions of DPDPE were sufficient to stimulate responding (treatment × lever: *F*~4,97~ = 2.41, *p* = 0.05; treatment: *F*~4,97~ = 6.51, *p* \< 0.001; lever: *F*~1,97~ = 40.91, *p* \< 0.001), with increases in responding on both the drug-paired lever (*F*~4,38~ = 4.61, *p* = 0.004) and inactive lever (*F*~4,38~ = 3.43, *p* = 0.017). It should be noted, however, that the 300 ng/side dose of DPDPE elicited twice as much responding in the NAc than in the CPu. In addition, intra-CPu pretreatment with CTAP at a dose that blocked cocaine-primed reinstatement in the NAc failed to alter cocaine seeking when infused into the CPu ([Figure 6b](#F6){ref-type="fig"}) compared to vehicle-pretreated animals (treatment × lever: *F*~1,14~ = 0.08, *p* = NS; treatment: *F*~1,14~ = 0.09, *p* = NS; lever: *F*~1,14~ = 10.21, *p* \< 0.01). Together, these data indicate that MOR involvement in reinstatement of cocaine seeking is specific to the NAc, while DOR in both sites are capable of triggering this behavior.

Opioid agonist induction of locomotor behavior in cocaine-trained animals {#S17}
-------------------------------------------------------------------------

Following 1 week withdrawal from cocaine self-administration and reinstatement testing, the locomotor response to intracranial infusions of DAMGO, DPDPE, β-endorphin and thiorphan was tested using doses that produced peak and primarily drug-paired lever responding when infused in the NAc. [Figure 7a and 7b](#F7){ref-type="fig"} show that all treatments increased locomotion for 1 h after infusion into the NAc when compared to vehicle infusions (*F*~4,46~ = 8.429, *p* \< 0.001), while only β-endorphin increased locomotion for at least 2 h after infusion (*F*~4,41~ = 8.258, *p* \< 0.001). Thus, the lower doses of DAMGO and DPDPE that triggered cocaine seeking produced psychomotor effects without the delay typically observed with higher doses in previous studies. [Figures 7c and 7d](#F7){ref-type="fig"} show that very similar locomotor responses were produced by infusions of DPDPE and β-endorphin in the CPu (*F*~4,16~ = 5.427, *p* = 0.006), with a trend for thiorphan to increase locomotor activity during the first hour (*p* = 0.059). In contrast, intra-CPu infusions of DAMGO failed to significantly increase locomotion. Together, these findings suggest that while psychomotor activation may accompany reinstatement of cocaine seeking with NAc infusions, similar locomotor responses with CPu infusions are dissociated from cocaine seeking in many cases.

Injection Sites {#S18}
---------------

[Figure 8](#F8){ref-type="fig"} illustrates the localization of all infusion sites in the NAc and CPu used in this study. Fourteen animals were eliminated from NAc studies, and 3 animals were eliminated from CPu studies, due to misplacement of one or both cannulae.

Discussion {#S19}
==========

This study found that selective stimulation of either MOR or DOR in the NAc is sufficient to reinstate cocaine-seeking behavior in rats following extinction of cocaine self-administration. Thus, NAc infusions of either the MOR-selective agonist DAMGO or the DOR-selective agonist DPDPE effectively elicited cocaine-seeking responses on the drug-paired lever that delivered cocaine injections during prior self-administration. The threshold dose for reinstating cocaine seeking was 300 times lower with DAMGO (1 ng/side) than with DPDPE (300 ng/side), while DPDPE induced greater peak rates of responding and was associated with generalized but lower rates of responding on the inactive lever. This latter effect with DPDPE could be related to psychomotor activation rather than motivation for cocaine, or an inability to appropriately discriminate the drug-paired from inactive levers with increased DOR stimulation, although a lower dose of DPDPE selectively induced responding on the drug-paired lever. Both of these metabolically stable opioid peptide agonists produced an inverted U-shaped dose-response curve indicating that higher doses were ineffective, potentially explaining the failure to detect morphine-induced reinstatement of drug seeking at microgram doses used in previous studies ([@R69]; [@R74]).

In contrast, intra-NAc infusions of the endogenous opioid peptide β-endorphin induced cocaine seeking with a monophasic dose-response curve up to 1 μg/side, possibly reflecting the sensitivity of this peptide to metabolic degradation. Importantly, the reinstating effects of both DAMGO and β-endorphin were blocked by the MOR-selective antagonist CTAP, and not by the DOR-selective antagonist naltrindole. The ability of DAMGO and β-endorphin to reinstate cocaine seeking was localized to the NAc, since the failure of more dorsal CPu infusions to reinstate responding negates the possibility of diffusion along the cannulae shaft or into the cerebral ventricles. These data firmly establish that MOR in the NAc mediate relapse to cocaine-seeking behavior. While stimulation of MOR in dorsomedial CPu is ineffective, dorsolateral CPu sites could be involved in cocaine seeking given that inactivation of this site reduces cocaine-seeking behavior ([@R58]).

In addition, infusions of CTAP into the NAc, but not the CPu, attenuated cocaine-primed reinstatement, possibly relating to the ability of cocaine to increase endogenous β-endorphin release in the NAc ([@R42]; [@R54]). Higher doses of CTAP (3 μg) were required to attenuate cocaine-primed reinstatement than DAMGO-primed reinstatement (30 ng), possibly reflecting higher concentrations of cocaine-induced β-endorphin release relative to the very low doses of DAMGO that were effective (1--3 ng/side). The high dose of CTAP that attenuated cocaine-primed reinstatement also blocked β-endorphin-primed reinstatement that required a higher dose range (0.1 -- 1 μg) than found with DAMGO.

Cocaine-induced β-endorphin release in the NAc is blocked by dopamine receptor antagonist infusions in the arcuate nucleus of the hypothalamus ([@R16]), the primary source for β-endorphin innervation of the NAc. β-endorphin release in the NAc also is induced by exposure to footshock stress, or the unmet expectation of cocaine reward under extinction conditions ([@R54]; [@R81]), situations that elicit cocaine-seeking behavior. Thus, taken together with our findings, β-endorphin stimulation of MOR in the NAc could contribute to cocaine seeking elicited by cocaine priming, exposure to cocaine-associated environments, and stressful events. In contrast, a previous study found that NAc pretreatment with CTAP does not block cocaine-primed reinstatement using longer acting intraperitoneal cocaine priming injections ([@R74]), whereas effective blockade was found using shorter acting intravenous cocaine priming in our study. Another difference could involve the use of the within- versus between-session extinction/reinstatement paradigms.

Contrary to DAMGO and β-endorphin, cocaine seeking induced by DPDPE was blocked by pretreatment with DOR- but not the MOR-selective antagonist in the NAc. NAc infusions of the enkephalinase inhibitor thiorphan (to elevate endogenous enkephalins) also reinstated cocaine seeking, and the effect was blocked by DOR antagonist pretreatment, although marginal (non significant) attenuation was found with the MOR antagonist potentially relating to enkephalin activity at MOR. DOR stimulation in more dorsal CPu sites with DPDPE also induced a moderate degree of cocaine seeking, but with greater efficacy in the NAc. Moreover, the reinstating effect of DPDPE in the CPu was accompanied by significant inactive lever responding, an effect not found with this DPDPE dose in the NAc, and potentially relating to psychomotor activation as discussed above. In this regard, infusions of the enkephalinase inhibitor thiorphan in the CPu failed to reinstate cocaine seeking, and had no effect on inactive lever responding in either striatal site. Together, the double dissociation with MOR- and DOR-selective ligands clearly indicates that mu and delta opioid receptors in the NAc mediate cocaine seeking through distinct and independent mechanisms.

Interestingly, blockade of DOR in the NAc failed to attenuate cocaine-primed reinstatement of cocaine seeking. Whether cocaine increases extracellular enkephalins in the NAc is unknown, but cocaine acutely increases preproenkephalin expression throughout the striatum ([@R26]), although this acute effect is diminished with chronic cocaine administration ([@R3]; [@R37]). One study found that systemic administration of naltrindole decreases cocaine self-administration but only at doses that also suppressed locomotor behavior ([@R15]). Another study showed reduced lever pressing for cocaine irrespective of reinforcement schedule ([@R52]), and intra-NAc infusions of an irreversible DOR alkylating analog of naltrindole ([@R50]) decreased responding for cocaine on a more demanding progressive ratio schedule of reinforcement ([@R80]), suggesting generalized effects on motor performance. In contrast, icv administration of the naltrindole analog strongly reduced heroin self-administration while only modestly decreasing cocaine self-administration on a less demanding fixed ratio reinforcement schedule ([@R38]), suggesting that endogenous DOR activity plays little role in cocaine's effects. Similarly, our results are consistent with the notion that endogenous release of enkephalins in the NAc does not contribute to cocaine-primed reinstatement of cocaine seeking, but further tests are needed to determine whether cocaine seeking induced by stress or cocaine-associated cues involves endogenous enkephalinergic activity at NAc DOR.

Intra-NAc infusions of MOR and DOR agonists at doses that effectively reinstated cocaine seeking also increased horizontal locomotion, with β-endorphin infusions producing prolonged effects over 2-h of testing. Infusions of all treatments into the dorsomedial CPu also increased locomotion to similar levels, with the exception of the MOR agonist DAMGO, whereas only the DOR agonist DPDPE triggered cocaine seeking in this region. While these data support the notion that DPDPE-induced reinstatement may be related to psychomotor activation, the dissociation of locomotor activity and cocaine seeking with infusions of β-endorphin and thiorphan in the CPu suggest that the reinstating effects of these treatments in the NAc are not related to generalized psychomotor activation. Moreover, while it could be argued that DAMGO-induced reinstatement is related to psychomotor activation, the lack of increases in inactive lever responding with DAMGO infusions suggests that reinstatement reflects motivational rather than motor effects. In contrast to reinstatement of cocaine seeking, NAc infusions of higher doses of DAMGO (0.25 -- 2.5 μg) induce a delayed increase in locomotion and preference for sucrose and high fat foods often after a period of behavioral suppression ([@R13];[@R40]; [@R83]; [@R30]), whereas we found that very low doses induce locomotion and cocaine seeking without delay. These findings suggest that lower doses of DAMGO could be employed to elicit appetitive behavior without delay in future studies.

Although MOR and DOR are coupled to similar intracellular signaling pathways, their distinct involvement in modulating drug-seeking behavior can be attributed to differences in their sub-anatomical distribution. MOR are largely expressed extrasynaptically on dendrites and dendritic shafts of GABAergic and cholinergic cells within striatal patches ([@R72]; [@R79]) where they modulate excitatory and GABAergic input to NAc neurons ([@R24]). Presynaptic MOR can also modulate the release of GABA onto NAc neurons ([@R72]). DOR can either directly or indirectly modulate dopamine release through expression on dopamine terminals or on GABAergic terminals apposed to dopamine terminals. DOR also can modulate postsynaptic responses in spiny neurons that receive dopamine input ([@R71]). MOR co-localize predominantly with preprotachykinin positive neurons in patch compartments that constitute the direct striatal output, and more rarely with preproenkephalin positive neurons of the striatal matrix that constitute the indirect output ([@R19]). The differential expression patterns of MOR and DOR lend them different mechanisms of action, with DOR more frequently modulating inhibitory and dopaminergic input to the NAc and MOR primarily modulating NAc GABAergic neurons themselves ([@R71]; [@R72]; [@R78]).

Cocaine-primed reinstatement of cocaine seeking requires glutamatergic neurotransmission in the NAc core ([@R12]; [@R39]) and dopaminergic neurotransmission in the NAc shell ([@R1]), although direct dopamine receptor stimulation in the medial NAc core elicits greater cocaine seeking than the shell or lateral core region ([@R4], [@R55]). While we did not compare core with shell subregions in this study, the ability of the MOR antagonist CTAP to block cocaine-primed cocaine seeking suggests that β-endorphin is released in the vicinity of the medial NAc. Given that the locomotor activating effects of intra-NAc MOR- and DOR-selective agonists are not attenuated by dopamine depletion or chronic dopamine receptor blockade ([@R70]; [@R9]), it is likely that cocaine seeking elicited by MOR and DOR stimulation is mediated independent of dopamine release in the NAc. Furthermore, dopamine depletion leads to supersensitivity to MOR but not DOR agonist infusions in locomotor tests ([@R9]).

Chronic cocaine administration modulates opioid receptor expression in the NAc (for review see ([@R7]; [@R33]), suggesting that changes in these receptors could alter the propensity for relapse during cocaine withdrawal. Free β-endorphin levels are decreased in the NAc and other brain regions within 1 day withdrawal from cocaine self-administration, potentially reflecting depletion of endogenous stores ([@R73]). Similarly, opioid receptor binding decreases immediately after and prior to the next scheduled cocaine self-administration session ([@R21]), possibly reflecting the release of endogenous opioids during cocaine self-administration. Chronic cocaine administered in a daily binge pattern transiently increases MOR but not DOR density and MOR-stimulated \[35S\]GTPγS binding in the NAc ([@R57]; [@R77]). However, the ability of DOR, but not MOR, stimulation to inhibit adenylyl cyclase activity is impaired in the NAc following chronic cocaine ([@R76]), and this impairment persists for at least 1 day of cocaine withdrawal ([@R45]), coinciding with increased internalization of DOR in NAc neurons ([@R2]). While these changes could modify the ability of MOR and DOR to trigger cocaine relapse in early cocaine withdrawal, we reported that MOR, and not DOR, levels in the NAc core progressively increase from 1 to 6 weeks of withdrawal from chronic cocaine self-administration ([@R59]), and the effect is accompanied by increases in the precursor for β-endorphin, pro-opiomelanocortin, in the arcuate nucleus of the hypothalamus ([@R62]). These findings suggest that progressive increases in MOR signaling in the NAc contribute to time-dependent increases in cocaine seeking behavior in cocaine withdrawal when animals are exposed to cocaine-paired environments or stressful conditions ([@R25]; [@R65]; [@R75]).

Human studies also support a relationship between increased MOR and cocaine craving in abstinence. Thus, MOR binding measured by positron emission tomography is increased in striatal and cortical regions in abstinent cocaine addicts and positively correlates with measures of cocaine craving ([@R22]; [@R84]). In subsequent studies, the up-regulation in MOR binding was found to persist for up to 12 weeks of abstinence and positively correlate with the amount of prior cocaine use ([@R22]). Moreover, the up-regulation of MOR in abstinence served as an independent predictor of time to relapse in cocaine addicts, and positively correlated with amount of cocaine use during the first month of relapse ([@R23]). While limitations in detection precluded examination of MOR exclusively in the NAc, our animal data suggest that such long-lasting increases in MOR could functionally increase the propensity for cocaine relapse ([@R59]).

In this regard, treatment with the opioid receptor antagonist naltrexone in combination with behavioral therapy decreased cocaine use over time ([@R56]). When 3-fold higher doses of naltrexone were utilized in combination with psychosocial treatment, the severity of cocaine use decreased ([@R46]). In response to an acute cocaine dose, addicts reported decreased "good effects" and "crash" when treated with naltrexone ([@R32]; [@R64]), although naltrexone reportedly does not decrease subjective reports of craving elicited by cocaine-associated cues ([@R41]). Our findings suggest that blockade of MOR and DOR in the NAc contribute to the therapeutic potential of naltrexone in the treatment of cocaine addiction.
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![Intra-NAc infusions of (**a**) the mu-opioid receptor selective agonist DAMGO or (**b**) the delta-opioid receptor selective agonist DPDPE increase non-reinforced drug-paired lever responding in a within-session reinstatement procedure. Data represent the mean ± SEM for doses of DAMGO (*n* = 9--27 animals/treatment) and DPDPE (*n* = 5--22 animals/treatment). Symbols indicate drug-paired lever (\* *p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001) or inactive lever (^††^*p* \< 0.001) differs from vehicle-infused controls by Dunnett's *post-hoc* tests.](nihms93482f1){#F1}

![Intra-NAc pretreatment with (**a**) the mu-opioid receptor selective antagonist CTAP followed by 1 ng DAMGO and (**b**) the delta-opioid receptor selective antagonist naltrindol followed by 300 ng DPDPE dose-dependently attenuates reinstatement of cocaine seeking. Data represent the mean ± SEM for DAMGO/CTAP (*n* = 13--22 animals/treatment) and DPDPE/naltrindole (*n* =18--20 animals/treatment) combinations. Symbols indicate drug-paired lever (\*\**p* \< 0.01, \*\*\**p* ≤ 0.001) or inactive lever (^†^*p* \< 0.05) differs from agonist/vehicle-infused controls by Dunnett's *post-hoc* tests.](nihms93482f2){#F2}

![(**a**) Reinstatement induced by 1 ng DAMGO is blocked by intra-NAc pretreatment with CTAP and not naltrindole. (**b**) Reinstatement induced by 300 ng DPDPE is blocked by intra-NAc pretreatment with naltrindole and not CTAP. (**c**) Reinstatement induced by intravenous cocaine priming (2 mg/kg) is blocked by intra-NAc pretreatment with CTAP and not naltrindole. Data represent the mean ± SEM agonist/antagonist combinations (*n* = 12--40 animals/treatment). Symbols indicate drug-paired lever responses differ from agonist/vehicle-infused controls (\* *p* \< 0.05, \*\**p* \< 0.01) or CTAP differs from naltrindole (^†^*p* \< 0.05) by Tukey's HSD *post-hoc* tests.](nihms93482f3){#F3}

![Intra-NAc infusion of (**a**) the endogenous opioid peptide β-endorphin dose-dependently reinstates drug-paired lever responding, (**b**) whereas met-enkephalin has no effect. (**c**) Intra-NAc infusion of the enkephalinase inhibitor thiorphan significantly increases drug-paired lever responding. Data represent the mean ± SEM for doses of β-endorphin (*n* = 10--15 animals/treatment), met-enkephalin (*n* = 7--11 animals/treatment), and thiorphan (*n* = 10--15 animals/treatment). Symbols indicate drug-paired lever (\**p* \< 0.05, \*\*\**p* \< 0.001) or inactive lever (^†††^*p* \< 0.001) differs from vehicle-infused controls by Dunnett's *post-hoc* tests.](nihms93482f4){#F4}

![(**a**) Reinstatement induced by 1 μg β-endorphin is blocked by intra-NAc pretreatment with CTAP or naloxone, but not naltrindole. (**b**) Reinstatement induced by 3 μg thiorphan is blocked by intra-NAc pretreatment with naltrindole or naloxone, but not CTAP. Data represent the mean ± SEM for β-endorphin/antagonist (*n* = 9--17 animals/treatment) and thiorphan/antagonist (n = 8--14 animals/treatment) combinations. Symbols indicate drug-paired lever responses differ from agonist/vehicle-infused controls (\**p* \< 0.05, \*\*\**p* \< 0.001) or differs from naltrindole (^†^*p* \< 0.05) by Tukey's HSD *post-hoc* tests.](nihms93482f5){#F5}

![(**a**) Effective NAc doses of DAMGO, β-endorphin and thiorphan are ineffective at reinstatement when infused in the CPu, while intra-CPu DPDPE induces significant drug-paired and inactive lever responding. (**b**) Pretreatment with intra-CPu infusions of CTAP has no effect on reinstatement induced by intravenous cocaine priming (2 mg/kg). Data represent the mean ± SEM for doses of agonists (*n* = 7--18 animals/treatment) and cocaine/antagonist (*n* = 6--8 animals/treatment) combinations. Symbols indicate drug-paired lever responses (\*\**p* \< 0.01) or inactive lever responses (^†^*p* \< 0.05) differ from vehicle-infused controls by Dunnett's *post-hoc* tests.](nihms93482f6){#F6}

![Effects of reinstating doses of agonist treatments on horizontal locomotion in cocaine-trained animals. **(a)** Timeline of locomotor behavior during habituation for 2 h and following intra-NAc infusion of opioid agonist. **(b)** All agonists increase locomotor behavior for 1 h when infused in the NAc while β-endorphin activity remains elevated during the second h of testing. **(c)** Timeline of locomotor behavior in response to intra-CPu infusion of opioid agonists. **(d)** Only DPDPE and β-endorphin increased locomotor responding in the CPu with a trend for thiorphan to increase locomotion. Data represent the mean ± SEM for NAc (*n* = 7--13 animals/treatment) and CPu (n = 4--5 animals/treatment). Symbols indicate (\**p* \< 0.05, \*\* *p \<* 0.01, \*\*\**p* \< 0.001, ^†^*p* = 0.059) differs from vehicle-infused controls by Dunnett's *post-hoc* tests.](nihms93482f7){#F7}

![Localization of infusion sites in the medial NAc core and CPu (+1.2 through +2.2 mm from Bregma, [@R43]).](nihms93482f8){#F8}
